Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

The mechanisms responsible for garlic - drug interactions and their in vivo relevance.

Berginc K, Kristl A.

Curr Drug Metab. 2013 Jan;14(1):90-101.

PMID:
21838705
2.
3.

In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients.

Berginc K, Žakelj S, Kristl A.

Eur J Nutr. 2010 Sep;49(6):373-84. doi: 10.1007/s00394-010-0095-x. Epub 2010 Feb 7.

PMID:
20140680
4.

Garlic flavonoids and organosulfur compounds: impact on the hepatic pharmacokinetics of saquinavir and darunavir.

Berginc K, Milisav I, Kristl A.

Drug Metab Pharmacokinet. 2010;25(6):521-30. Epub 2010 Oct 1.

5.

HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy.

Berginc K, Trdan T, Trontelj J, Kristl A.

Biopharm Drug Dispos. 2010 Nov;31(8-9):495-505. doi: 10.1002/bdd.730. Epub 2010 Oct 26.

PMID:
21104925
6.

Transwell-grown HepG2 cell monolayers as in vitro permeability model to study drug-drug or drug-food interactions.

Berginc K, Kristl A.

J Med Food. 2011 Jan-Feb;14(1-2):135-9. doi: 10.1089/jmf.2010.0041. Epub 2010 Dec 7.

PMID:
21138349
7.

In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.

Patel J, Buddha B, Dey S, Pal D, Mitra AK.

Am J Ther. 2004 Jul-Aug;11(4):262-77.

PMID:
15266218
9.

Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.

Goey AK, Mooiman KD, Beijnen JH, Schellens JH, Meijerman I.

Cancer Treat Rev. 2013 Nov;39(7):773-83. doi: 10.1016/j.ctrv.2012.12.008. Epub 2013 Feb 8. Review.

PMID:
23394826
10.

Aged garlic extract stimulates p-glycoprotein and multidrug resistance associated protein 2 mediated effluxes.

Berginc K, Zakelj S, Ursic D, Kristl A.

Biol Pharm Bull. 2009 Apr;32(4):694-9.

12.

Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans.

Hajda J, Rentsch KM, Gubler C, Steinert H, Stieger B, Fattinger K.

Eur J Pharm Sci. 2010 Dec 23;41(5):729-35. doi: 10.1016/j.ejps.2010.09.016. Epub 2010 Oct 7.

PMID:
20933082
13.
15.

Interaction of Rhei Rhizoma extract with cytochrome P450 3A and efflux transporters in rats.

Yokooji T, Kida M, Mori M, Akashi H, Mori N, Yoshihara S, Murakami T.

Pharmazie. 2010 May;65(5):367-74.

PMID:
20503931
16.

Targeting intestinal transporters for optimizing oral drug absorption.

Varma MV, Ambler CM, Ullah M, Rotter CJ, Sun H, Litchfield J, Fenner KS, El-Kattan AF.

Curr Drug Metab. 2010 Nov;11(9):730-42. Review.

PMID:
21189135
17.

Active intestinal absorption of fluoroquinolone antibacterial agent ciprofloxacin by organic anion transporting polypeptide, Oatp1a5.

Arakawa H, Shirasaka Y, Haga M, Nakanishi T, Tamai I.

Biopharm Drug Dispos. 2012 Sep;33(6):332-41. doi: 10.1002/bdd.1809. Epub 2012 Aug 30.

PMID:
22899169
18.

Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells.

Makhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko PJ.

Pharm Res. 1998 Aug;15(8):1160-7.

PMID:
9706044
19.

Transporters and drug-drug interactions: important determinants of drug disposition and effects.

König J, Müller F, Fromm MF.

Pharmacol Rev. 2013 May 17;65(3):944-66. doi: 10.1124/pr.113.007518. Print 2013 Jul. Review.

20.

Oral drug delivery utilizing intestinal OATP transporters.

Tamai I.

Adv Drug Deliv Rev. 2012 May 1;64(6):508-14. doi: 10.1016/j.addr.2011.07.007. Epub 2011 Jul 30. Review.

PMID:
21824501

Supplemental Content

Support Center